Article
PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients.
Antimicrobial agents and chemotherapy - 1 Dec 2011
Miller Amanda K, Brannon Mark K, Stevens Laurel, Johansen Helle Krogh, Selgrade Sara E, Miller Samuel I, Høiby Niels, Moskowitz Samuel M
Abstract excerpt
Pseudomonas aeruginosa can develop resistance to polymyxin and other cationic antimicrobial peptides. Previous work has shown that mutations in the PmrAB and PhoPQ regulatory systems can confer low to moderate levels of polymyxin resistance (MICs of 8 to 64 mg/liter) in laboratory and clinical strains of this organism. To explore the role of PhoPQ in high-level clinical polymyxin resistance, P. aeruginosa strains...
Topics
- Anti-Bacterial Agents
- Bacterial Proteins
- Colistin
- Cystic Fibrosis
- Drug Resistance, Bacterial
- Female
- Humans
- Lipid A
- Male
- Microbial Sensitivity Tests